Cellectis SA (NASDAQ:CLLS) shares traded down 9.6% during trading on Friday . The company traded as low as $23.95 and last traded at $24.16, with a volume of 281,943 shares trading hands. The stock had previously closed at $26.72.

A number of research analysts recently commented on the company. Zacks Investment Research lowered Cellectis SA from a “buy” rating to a “hold” rating in a research note on Thursday, March 17th. Oppenheimer Holdings Inc. restated a “buy” rating on shares of Cellectis SA in a research note on Tuesday, May 31st. Piper Jaffray Cos. restated a “buy” rating on shares of Cellectis SA in a research note on Wednesday, March 16th. Finally, Ladenburg Thalmann assumed coverage on Cellectis SA in a research note on Tuesday, April 5th. They issued a “buy” rating and a $45.00 target price for the company. One research analyst has rated the stock with a sell rating and five have assigned a buy rating to the stock. The stock currently has an average rating of “Buy” and a consensus price target of $44.67.

The company has a 50-day moving average of $29.31 and a 200 day moving average of $26.96. The firm’s market capitalization is $885.98 million.

Cellectis SA (NASDAQ:CLLS) last announced its earnings results on Thursday, May 12th. The company reported ($0.53) EPS for the quarter, missing the consensus estimate of ($0.35) by $0.18. Analysts anticipate that Cellectis SA will post ($2.11) earnings per share for the current fiscal year.

A hedge fund recently raised its stake in Cellectis SA stock. Tekla Capital Management LLC raised its stake in shares of Cellectis SA (NASDAQ:CLLS) by 30.9% during the fourth quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The firm owned 207,250 shares of the company’s stock after buying an additional 48,868 shares during the period. Tekla Capital Management LLC owned approximately 0.59% of Cellectis SA worth $6,431,000 at the end of the most recent quarter.

Cellectis SA is a France-based company active in the field of genome engineering and genomic surgery. The Company specializes in the research, development and commercialization of rational genome engineering technologies. It has developed an expertise in combining meganucleases with engineered targeting Deoxyribonucleic Acid (DNA) matrices into Meganuclease Recombination Systems (MRS), used for gene excision, correction or replacement.

Get Analysts' Upgrades and Downgrades Daily - Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.